目的 探討氣滯胃痛顆粒聯(lián)合鋁碳酸鎂咀嚼片治療慢性胃炎的臨床療效。方法 選取2018年1月-2019年11月在鄭州新鄭國際機場急救中心就診的130例慢性胃炎患者作為研究對象，按照隨機數(shù)字表法將130例患者分為對照組和治療組，每組各有65例。對照組口服鋁碳酸鎂咀嚼片，1.0 g/次，3次/d。治療組在對照組基礎(chǔ)上口服氣滯胃痛顆粒，5 g/次，3次/d。兩組患者連續(xù)治療8周。觀察兩組患者的療效，比較兩組的腹痛消失時間、腹脹消失時間、反酸消失時間，對比兩組患者炎癥因子[C反應(yīng)蛋白（CRP）、白細胞介素-17（IL-17）、細胞間黏附分子-1（ICAM-1）]和胃腸激素[胃動素（MTL）、胃泌素（GAS）、生長抑素（SS）]水平。結(jié)果 治療后，治療組患者的總有效率（95.38%）比對照組高（84.62%），差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，治療組的腹痛消失時間、腹脹消失時間、反酸消失時間比對照組低，差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組的CRP、IL-17、ICAM-1水平均明顯降低（P<0.05）；治療后治療組患者的CRP、IL-17、ICAM-1水平低于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組的MTL、GAS均明顯降低，SS明顯升高（P<0.05）；治療后治療組的MTL、GAS水平比對照組低，SS比對照組高，差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 氣滯胃痛顆粒聯(lián)合鋁碳酸鎂咀嚼片治療慢性胃炎的療效確切，可減輕患者的臨床癥狀，調(diào)節(jié)胃腸激素的分泌，降低炎癥因子水平，具有一定的臨床研究價值。

Objective To explore the clinical effect of Qizhi Weitong Granules combined with Hydrotalcite Chewable Tablets in treatment of chronic gastritis. Methods Patients (130 cases) with chronic gastritis in Zhengzhou Xinzheng International Airport Emergency Center from January 2018 to November 2019 were randomly divided into control and treatment groups, and each group had 65 cases. Patients in the control group were po administered with Hydrotalcite Chewable Tablets, 1.0 g/time, three daily. Patients in the treatment group were po administered with Qizhi Weitong Granules on the basis of the control group, 5 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and the disappearance time of abdominal pain, abdominal distention and acid regurgitation were compared. The levels of inflammatory factors (CRP, IL-17, and ICAM-1) and gastrointestinal hormones (MTL, gas, and SS) were compared. Results After treatment, the total effective rate of the treatment group (95.38%) was higher than that of the control group (84.62%), and the difference was statistically significant (P<0.05). After the treatment, the disappearance times of abdominal pain, abdominal distention and acid regurgitation in the treatment group were lower than those in the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of CRP, IL-17, and ICAM-1 in two groups were significantly lower (P<0.05). After treatment, the levels of CRP, IL-17, and ICAM-1 in the treatment group were lower than those in the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of MTL and GAS in two groups were significantly decreased, and the levels of SS in two groups were significantly increased (P<0.05). After treatment, the levels of MTL and GAS in the treatment group were lower than those in the control group, and the levels of SS in the treatment group were higher than those in the control group, and the difference was statistically significant (P<0.05). Conclusion Qizhi Weitong Granules combined with Hydrotalcite Chewable Tablets has clinical curative effect in treatment of chronic gastritis, can reduce the clinical symptoms of patients, regulate the secretion of gastrointestinal hormones, reduce the level of inflammatory factors, which has a certain clinical research value.

R975